Cyclophosphamide and Cryoablation in Treating Patients With Advanced or Metastatic Epithelial Cancer
RATIONALE: Drugs used in chemotherapy, such as cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Cryoablation kills cancer cells by freezing them. Giving chemotherapy together with cryoablation may kill more cancer cells. PURPOSE: This clinical trial is studying how well giving cyclophosphamide together with cryoablation works in treating patients with advanced or metastatic epithelial cancer.
Checked against the public recordLast updated Jan 18, 2019 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Early Phase 1
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Interventions being studied
- Drug: cyclophosphamide; Device: Cryoablation
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
DISEASE CHARACTERISTICS: * Diagnosis of epithelial solid tumors of any of the following sites or types: * Lung (closed to accrual as of 4/2/2009) * Renal * Prostate * Breast (closed to accrual as of 4/2/2009) * Sarcoma (closed to accrual as of 4/2/2009) * Colon (closed to accrual as of 4/2/2009) * Liver(closed to accrual as of 4/2/2009) * Pancreatic (closed to accrual as of 4/2/2009) * Bone (closed to accrual as of 4/2/2009) * Head and neck (closed to accrual as of 4/2/2009) * Melanoma (closed to accrual as of 4/2/2009) * Carcinoma of unknown primary (closed to accrual as of 4/2/2009) * Advanced or metastatic disease * Ineligible for or unwilling to undergo surgical resection * Eligible for cryotherapy but not expected to be cured by cryotherapy alone PATIENT CHARACTERISTICS: * ECOG performance status 0-2 * Life expectancy \> 3 months * Creatinine \< 2.5 mg/dL * Platelet count \>75,000/mm³ * INR\< 1.5 * No known HIV positivity * No active, uncontrolled infection * Not pregnant * Negative pregnancy test * Women of childbearing potential must practice adequate contraception * No debilitating medical or psychiatric illness that would preclude giving informed consent or receiving optimal treatment and follow-up PRIOR CONCURRENT THERAPY: * See Disease Characteristics
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Brady Urological Institute at Johns Hopkins HospitalBaltimore, Maryland
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Jan 18, 2019. Always confirm current availability with the study team.